retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial A review of an investigational drug retatrutide, a novel agent for the treatment of | European Journal of Clinical Pharmacology Beyond GLP-1: Retatrutide's triple-agonist mechanism
Pay in 4 interest-free payments of $6.03 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19

01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)










00174-1/asset/78f65028-19d3-4307-9d22-cec15077f8ce/main.assets/gr3_lrg.jpg)













